^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CXCR2 and NGFR transduced TIL

    i
    Other names: CXCR2 and NGFR transduced TIL, T-Cells transduced with CXCR2, CXCR2-transduced autologous tumor infiltrating lymphocytes, T-Cells transduced with CXCR2 and NGFR, T-cells transduced with chemokine (C-X-C motif) receptor 2 and nerve growth factor receptor
    Associations

    News

    Trials
    Company:
    UT MD Anderson Cancer Center
    Drug class:
    CXCR2 antagonist, Nerve growth factor antagonist
    Related drugs:
    Associations

    News

    Trials
    1year
    NCI-2014-02655: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=10, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2024 --> Apr 2023 | Trial primary completion date: Jan 2024 --> Apr 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • NGFR (Nerve Growth Factor Receptor) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • CXCR2 and NGFR transduced TIL
    over2years
    NCI-2014-02655: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2021 --> Jan 2024 | Trial primary completion date: Jan 2021 --> Jan 2024
    Clinical • Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • NGFR (Nerve Growth Factor Receptor) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • CXCR2 and NGFR transduced TIL
    4years
    Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=15 --> 10 | Trial primary completion date: Jan 2020 --> Jan 2021
    Clinical • Enrollment closed • Enrollment change • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • NGFR (Nerve Growth Factor Receptor) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    |
    fludarabine IV • Proleukin (aldesleukin) • CXCR2 and NGFR transduced TIL • cyclophosphamide intravenous